Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients
Cucchiari, David ![ORCID Identifier](/img/uab/orcid.ico)
(Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Egri, Natalia (Hospital Clínic i Provincial de Barcelona)
Bodro, Marta ![ORCID Identifier](/img/uab/orcid.ico)
(Hospital Clínic i Provincial de Barcelona)
Herrera, Sabina (Hospital Clínic i Provincial de Barcelona)
Del Risco-Zevallos, Jimena (Hospital Clínic i Provincial de Barcelona)
Casals-Urquiza, Joaquim (Hospital Clínic i Provincial de Barcelona)
Cofan, Frederic
(Hospital Clínic i Provincial de Barcelona)
Moreno Camacho, Asunción
(Hospital Clínic i Provincial de Barcelona)
Rovira, Jordi
(Red de Investigación Renal (REDINREN))
Banon-Maneus, Elisenda (Red de Investigación Renal (REDINREN))
Ramirez-Bajo, Maria J.. (Red de Investigación Renal (REDINREN))
Ventura-Aguiar, Pedro
(Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Pérez-Olmos, Anna (Hospital Clínic i Provincial de Barcelona)
Garcia-Pascual, Marta (Hospital Clínic i Provincial de Barcelona)
Pascal, Mariona
(Instituto de Salud Carlos III)
Vilella, Anna
(Hospital Clínic i Provincial de Barcelona)
Trilla, Antoni (Hospital Clínic i Provincial de Barcelona)
Ríos, José
(Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
Palou, Eduard
(Hospital Clínic i Provincial de Barcelona)
Juan, Manel
(Hospital Clínic i Provincial de Barcelona)
Bayés Genís, Beatriu (Hospital Clínic i Provincial de Barcelona)
Diekmann, Fritz
(Red de Investigación Renal (REDINREN))
Date: |
2021 |
Abstract: |
According to preliminary data, seroconversion after mRNA SARS-CoV-2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a certain grade of protection against SARS-CoV-2. To answer this question, we prospectively studied 148 recipients of either kidney (133) or kidney-pancreas (15) grafts with assessment of IgM/IgG spike (S) antibodies and ELISpot against the nucleocapside (N) and the S protein at baseline and two weeks after receiving the second dose of the mRNA-1273 (Moderna) vaccine. At baseline, 31 patients (20. 9%) had either IgM/IgG or ELISpot positivity and were considered to be SARS-CoV-2-pre-immunized, while 117 (79. 1%) patients had no signs of either cellular or humoral response and were considered SARS-CoV-2-naïve. After vaccination, naïve patients who developed either humoral or cellular response were finally 65. 0%, of which 29. 9% developed either IgG or IgM and 35. 0% S-ELISpot positivity. Factors associated with vaccine unresponsiveness were diabetes and treatment with anti-thymocytes globulins during the last year. Side effects were consistent with that of the pivotal trial and no DSAs developed after vaccination. In conclusion, mRNA-1273 SARS-CoV-2 vaccine elicits either cellular or humoral response in almost two thirds of KTRs. |
Rights: |
Tots els drets reservats. ![](/img/licenses/InC.ico) |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió acceptada per publicar |
Subject: |
Clinical research/practice ;
Infection and infectious agents-viral ;
Infectious disease ;
Kidney transplantation/nephrology ;
Vaccine |
Published in: |
American Journal of Transplantation, Vol. 21 Num. 5 (may 2021) , ISSN 1600-6143 |
DOI: 10.1111/ajt.16701
PMID: 34036720
The record appears in these collections:
Articles >
Research articlesArticles >
Published articles
Record created 2021-07-05, last modified 2024-01-08